Lodosyn
(Carbidopa)ApprovedSmall molecule
Carbidopa is used together with levodopa to treat Parkinson's disease by helping more of the levodopa reach the brain where it can work better to reduce symptoms like tremors and stiffness.[2] Lodosyn is currently approved and in use across 23 indications[4].[1]
Lodosyn is one of 400 small molecule programs targeting Injury. It is currently in Approved.
23
Indications
23
Total Trials
1
Active Trials
399
Competitors
1
FDA Application
NDA/BLA/ANDA regulatory filings
Pipeline
Status by Indication[4][1]
Indication
Showing 10 of 22 indications
Competition
Competitive Landscape
174 competitors in Schizophrenia
#DrugCompanyPhaseTrials
1Lodosyn
LLaTonya J. Hickson
Approved
Ozempic
Novo NordiskPreclinical
Resotran
TakedaPreclinical
Inapsine
Jazz PharmaceuticalsPreclinical
Depakote
AbbViePreclinical
Ibrance
PfizerPreclinical
Lunesta
Akero TherapeuticsPreclinical
Luvox
SSolvay Pharmaceuticals
Preclinical
Catapres
Boehringer IngelheimPreclinical
Persantine
Boehringer IngelheimPreclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Mobility3 trials
Idiopathic Parkinson's Disease2 trials
Parkinson's Disease2 trials
CAR2 trials
12 more indications
Fibromyalgia1 trial
Familial dysautonomia1 trial
Asthma1 trial
Single Dose1 trial
Cocaine Dependence1 trial
Multiple Sclerosis1 trial
Parkinsonism1 trial
Spinal Cord Injuries1 trial
Regulatory
FDA Approval Timeline[5]
Jan 1, 1982
LODOSYN
NDA NDA017830
Sources
References
- [1]
- [2]MedlinePlus Drug Information — Lodosyn drug information. U.S. National Library of Medicine, National Institutes of Health.
- [3]
- [4]Open Targets Platform — Drug–disease associations for Carbidopa. EMBL-EBI & Wellcome Sanger Institute.
- [5]
- [6]
Details
Drug Info
Quick Facts
- Mechanism of Action
- DOPA Decarboxylase Inhibitor[3]
- Modality
- Small molecule[3]
- Highest Phase
- Approved[1]
- Company
- LLaTonya J. Hickson